November 26, 2024

New Member: Welcome in our cluster to Myotwin GmbH

New Member: Welcome in our cluster to Myotwin GmbH
Go back

At Myotwin, the vision is to revolutionize drug development through innovation and compassion. The team is creating a digital twin of the human heart muscle, built from extensive high-content datasets, to enable animal-free drug testing. This groundbreaking platform aims to reshape pharmaceutical research by offering ethical, precise, and effective drug testing methods. By leveraging technology and data-driven insights, myotwin seeks to advance safer treatments while promoting animal welfare.

If you would like to learn more, please visit their Website.
Looking forward to your active participation!

Our latest News

discover more
Prof. Gudrun Rappold receives medal of honor from the German Society for Human Genetics

Prof. Gudrun Rappold receives medal of honor from the German Society for Human Genetics

Prof. Dr. Gudrun Rappold, senior professor at Heidelberg University’s Medical Faculty, has been awarded the Medal of Honor by the German Society for Human Genetics. The Medal of Honor is the highest award given by the professional association and recognizes outstanding scientific achievements in human genetics as well as special contributions to the advancement of […]

read more
How cancer immunotherapies affect the heart

How cancer immunotherapies affect the heart

The Hector Foundation is providing €1.3 million in funding for an interdisciplinary research project investigating the cardiological side effects of checkpoint inhibitors. The consortium, with partners at Heidelberg University’s Medical Faculty, the German Cancer Research Center, the Max Delbrück Center in Berlin, and the University Medical Center Schleswig-Holstein in Kiel, is investigating why these cancer […]

read more
Early detection contributes to declining breast cancer mortality rates in Europe

Early detection contributes to declining breast cancer mortality rates in Europe

The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by one of the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the German Cancer Research Center (DKFZ). The most […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp